FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Alfonso Quintás-Cardama

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Treatment Outcome

Physiology

Co-author Network

Publications

TOP 3
Alfonso Quintás-Cardama; Jorge Cortes; Hagop Kantarjian; Sherry Pierce; Srdan Verstovsek
Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia.
Aref Al-Kali; Gautam Borthakur; Carlos E Bueso-Ramos; Jorges Cortes; Zeev Estrov; Stefan Faderl; Elias Jabbour; Tapan Kadia; Hagop Kantarjian; Raja Luthra; Sherry Pierce; Alfonso Quintás-Cardama; Farhad Ravandi; Ayalew Tefferi; Guillermo Garcia-Manero
Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.
Alfonso Quintás-Cardama; Elias J Jabbour
Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Alfonso Quintás-Cardama (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Alfonso Quintás-Cardama; Jorge Cortes; Hagop Kantarjian; Sherry Pierce; Srdan Verstovsek
Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia.
Clinical lymphoma, myeloma & leukemia 2013;13(3):315-318.e2.
2013: Aref Al-Kali; Gautam Borthakur; Carlos E Bueso-Ramos; Jorges Cortes; Zeev Estrov; Stefan Faderl; Elias Jabbour; Tapan Kadia; Hagop Kantarjian; Raja Luthra; Sherry Pierce; Alfonso Quintás-Cardama; Farhad Ravandi; Ayalew Tefferi; Guillermo Garcia-Manero
Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.
American journal of hematology 2013;88(5):365-9.
2013: Alfonso Quintás-Cardama; Elias J Jabbour
Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib.
Leukemia research 2013;37(5):487-95.
2013: Alfonso Quintás-Cardama; Srdan Verstovsek
Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(8):1933-40.
2013: Alfonso Quintás-Cardama
The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: therapeutic implications.
Leukemia research 2013;37(4):465-72.
2013: Michael S Mathisen; Farhad Ravandi; Gautam Borthakur; Jorge E Cortes; Stefan Faderl; Guillermo Garcia-Manero; Elias Jabbour; Hagop Kantarjian; Alfonso Quintás-Cardama
Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.
Clinical lymphoma, myeloma & leukemia 2013;13(2):139-43.
2012: Vinod Pant; Alfonso Quintás-Cardama; Guillermina Lozano
The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans.
Blood 2012;120(26):5118-27.
2012: Alfonso Quintás-Cardama; Farhad Ravandi; Theresa Liu-Dumlao; Sherry Pierce; Gautam Borthakur; Mark Brandt; Jorge Cortes; Stefan Faderl; Guillermo Garcia-Manero; Hagop Kantarjian
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
Blood 2012;120(24):4840-5.
2012: Alfonso Quintás-Cardama; Hagop Kantarjian; Jorge Cortes
Nilotinib-associated vascular events.
Clinical lymphoma, myeloma & leukemia 2012;12(5):337-40.
2012: Wei-Gang Tong; William Wierda; Gautam Borthakur; Carlos Bueso-Ramos; Stefan Faderl; Elias Jabbour; Tapan Kadia; Hagop Kantarjian; Sherry Pierce; Alfonso Quintás-Cardama; Farhad Ravandi; Jianqin Shan; Guillermo Garcia-Manero
Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system.
Cancer 2012;118(18):4462-70.
2012: Alfonso Quintás-Cardama; Gautam Borthakur; Jorge Cortes; Zeev Estrov; Hagop Kantarjian; Srdan Verstovsek
Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis.
Leukemia research 2012;36(9):1124-7.
2012: Elias J Jabbour; Alfonso Quintás-Cardama
Molecular monitoring 101: helping your patients with chronic myeloid leukemia to understand the meaning of molecular response.
Leukemia & lymphoma 2012;53(8):1452-60.
2012: Xiaodong Cheng; Emil J Freireich; Ming-Zhang Gao; Mirna Golemovic; Hagop M Kantarjian; Alfonso Quintás-Cardama; Michael Andreeff; Ralph Zingaro; Srdan Verstovsek
The organic arsenic derivative GMZ27 induces PML-RARα-independent apoptosis in myeloid leukemia cells.
Anticancer research 2012;32(7):2871-80.
2012: James G Jackson; Qin Li; Yi Li; Taghi Manshouri; Vinod Pant; Alfonso Quintás-Cardama; Omid Tavana; Peirong Yang; Leslie L Chang; Adel K El-Naggar; Daniel Garza; Guillermina Lozano
p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.
Cancer cell 2012;21(6):793-806.
2012: Alfonso Quintás-Cardama; Andrew Lamb; Jorge Cortes
Bosutinib for the treatment of chronic myeloid leukemia in chronic phase.
Drugs of today (Barcelona, Spain : 1998) 2012;48(3):177-88.
2012: Alfonso Quintás-Cardama; Srdan Verstovsek
Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.
Cancer 2012;118(4):870-7.
2011: Alfonso Quintás-Cardama; Nitin Jain; Srdan Verstovsek
Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis.
Cancer 2011;117(24):5439-49.
2011: Alfonso Quintás-Cardama; Jorgé E Cortes; Hagop M Kantarjian
Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: long-term implications.
Cancer 2011;117(23):5261-70.
2011: Alfonso Quintás-Cardama; Jianqin Shan; Srdan Verstovsek; Lynne V Abruzzo; Guillermo Garcia-Manero; Elias Jabbour; Hagop Kantarjian; Susan O'Brien; Jorge Cortes
Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib.
Cancer 2011;117(22):5085-93.
2011: Elias Jabbour; Hagop M Kantarjian; Susan O'Brien; Alfonso Quintás-Cardama; Mary Beth Rios; Jianqin Shan; Guillermo Garcia-Manero; Jorge E Cortes
Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(32):4260-5.
2011: Jocelyn T De Yao; Guillermo Garcia-Manero; Ali Al-Ameri; Alfonso Quintás-Cardama
Infrequent presentations of mucormycosis in patients with myelodysplastic syndrome and acute leukemia: case series and review of literature.
Clinical lymphoma, myeloma & leukemia 2011;11(5):446-51.
2011: Alfonso Quintás-Cardama; Ying Zhang; Zeev Estrov; Amos Gaikwad; David Harris; Hagop M Kantarjian; Taghi Manshouri; Srdan Verstovsek
Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.
Investigational new drugs 2011;29(5):818-26.
2011: Tariq I Mughal; Alfonso Quintás-Cardama; Jerald P Radich; Farhad Ravandi; Tomasz Skorski; Daniel J DeAngelo; Carlo Gambacorti-Passerini; Giovanni Martinelli; Richard A Van Etten; Ayalew Tefferi
Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.
American journal of hematology 2011;86(9):811-9.
2011: Ali Al-Ameri; Mohamad Cherry; Guillermo Garcia-Manero; Alfonso Quintás-Cardama
Standard therapy for patients with myelodysplastic syndromes.
Clinical lymphoma, myeloma & leukemia 2011;11(4):303-13.
2011: Vinod Pant; Alfonso Quintás-Cardama; Shunbin Xiong; Tomoo Iwakuma; Guillermina Lozano
Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability.
Proceedings of the National Academy of Sciences of the United States of America 2011;108(29):11995-2000.
2011: Alfonso Quintás-Cardama; Srdan Verstovsek
New JAK2 inhibitors for myeloproliferative neoplasms.
Expert opinion on investigational drugs 2011;20(7):961-72.
2011: Taghi Manshouri; Zeev Estrov; Alfonso Quintás-Cardama; Jan Burger; Ying Zhang; Ana Livun; Liza Knez; David Harris; Chad J Creighton; Hagop M Kantarjian; Srdan Verstovsek
Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor.
Cancer research 2011;71(11):3831-40.
2011: Alfonso Quintás-Cardama; Hagop Kantarjian; Susan O'Brien; Elias Jabbour; Gautam Borthakur; Farhad Ravandi; Srdan Verstovsek; Jianqin Shan; Jorge Cortes
Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy.
Haematologica 2011;96(6):918-21.
2011: Fabio P S Santos; Alfonso Quintás-Cardama
New drugs for chronic myelogenous leukemia.
Current hematologic malignancy reports 2011;6(2):96-103.
2011: Alfonso Quintás-Cardama
JAK2 inhibitors in polycythemia vera.
Clinical advances in hematology & oncology : H&O 2011;9(5):397-400.
2011: Jorge Cortes; Alfonso Quintás-Cardama; Hagop M Kantarjian
Monitoring molecular response in chronic myeloid leukemia.
Cancer 2011;117(6):1113-22.
2011: Vince D Cataldo; Don L Gibbons; Román Pérez-Soler; Alfonso Quintás-Cardama
Treatment of non-small-cell lung cancer with erlotinib or gefitinib.
The New England journal of medicine 2011;364(10):947-55.
2011: Yongxing Wang; Young-Ah Suh; Maren Y Fuller; James G Jackson; Shunbin Xiong; Tamara Terzian; Alfonso Quintás-Cardama; James Bankson; Adel K El-Naggar; Guillermina Lozano
Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation.
The Journal of clinical investigation 2011;121(3):893-904.
2011: Alfonso Quintás-Cardama; Hagop Kantarjian; Jorge Cortes; Srdan Verstovsek
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.
Nature reviews. Drug discovery 2011;10(2):127-40.
2011: Alfonso Quintás-Cardama; F P S Santos; Guillermo Garcia-Manero
Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia.
Leukemia 2011;25(2):226-35.
2011: Jorge Cortes; Alfonso Quintás-Cardama; Dan Jones; Farhad Ravandi; Guillermo Garcia-Manero; Srdan Verstovsek; Charles Koller; Jody Hiteshew; Jenny Shan; Susan O'Brien; Hagop Kantarjian
Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor.
Cancer 2011;117(3):572-80.
2011: Aref Al-Kali; Hagop Kantarjian; Jianqin Shan; Roland Bassett; Alfonso Quintás-Cardama; Gautam Borthakur; Elias Jabbour; Srdan Verstovsek; Susan O'Brien; Jorge Cortes
Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia.
Cancer 2011;117(2):327-35.
2010: Alfonso Quintás-Cardama; Andrew Lamb; Jorge Cortes
Third-generation tyrosine kinase inhibitors and beyond.
Seminars in hematology 2010;47(4):371-80.
2010: Sean M Post; Alfonso Quintás-Cardama; Vinod Pant; Tomoo Iwakuma; Amir Hamir; James G Jackson; Daniela R Maccio; Gareth Bond; David G Johnson; Arnold J Levine; Guillermina Lozano
A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development.
Cancer cell 2010;18(3):220-30.
2010: Alfonso Quintás-Cardama; Fabio P S Santos; Guillermo Garcia-Manero
Therapy with azanucleosides for myelodysplastic syndromes.
Nature reviews. Clinical oncology 2010;7(8):433-44.
2010: Mirna Golemovic; Alfonso Quintás-Cardama; Taghi Manshouri; Nada Orsolic; Hatice Duzkale; Mary Johansen; Emil J Freireich; Andrew Lamb; Ralph A Zingaro; Srdan Verstovsek
MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells.
Investigational new drugs 2010;28(4):402-12.
2010: Sean M Post; Vinod Pant; Hussein Abbas; Alfonso Quintás-Cardama
Prognostic impact of the MDM2SNP309 allele in leukemia and lymphoma.
Oncotarget 2010;1(3):168-74.
2010: Alfonso Quintás-Cardama; Andrew Lamb; Jorge E Cortés
Applying cytogenetic and molecular information in the clinic: implications for the treatment of chronic myeloid leukemia.
Clinical lymphoma, myeloma & leukemia 2010;10 Suppl 1():S14-9.
2010: Sean M Post; Alfonso Quintás-Cardama
Closing in on the pathogenesis of the 5q- syndrome.
Expert review of anticancer therapy 2010;10(5):655-8.
2010: Alfonso Quintás-Cardama; Kris Vaddi; Phillip Liu; Taghi Manshouri; Jun Li; Peggy A Scherle; Eian Caulder; Xiaoming Wen; Yanlong Li; Paul Waeltz; Mark Rupar; Timothy Burn; Yvonne Lo; Jennifer Kelley; Maryanne Covington; Stacey Shepard; James D Rodgers; Patrick Haley; Hagop Kantarjian; Jordan S Fridman; Srdan Verstovsek
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
Blood 2010;115(15):3109-17.
2010: Meetu Agrawal; Ravin J Garg; Jorge Cortes; Alfonso Quintás-Cardama
Tyrosine kinase inhibitors: the first decade.
Current hematologic malignancy reports 2010;5(2):70-80.
2010: Alfonso Quintás-Cardama; Hesham M Amin; Andrew Lamb; Srdan Verstovsek
Treatment of aggressive systemic mastocytosis with daclizumab.
Leukemia & lymphoma 2010;51(3):540-2.
2010: Alfonso Quintás-Cardama; William Wierda; Susan O'Brien
Investigational immunotherapeutics for B-cell malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(5):884-92.
2010: Alfonso Quintás-Cardama; Theo Daniel Kim; Vince Cataldo; Philipp le Coutre
Nilotinib.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2010;184():103-17.
2009: Alfonso Quintás-Cardama; Andrew Lamb; Jorge Cortes
Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009.
Cancer 2009;115(23):5382-93.
2009: Ravin J Garg; Andrew Lamb; Susan O'Brien; Alfonso Quintás-Cardama; Stefan Faderl; Zeev Estrov; Jorge Cortes
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.
Blood 2009;114(20):4361-8.
2009: Alfonso Quintás-Cardama; Andrew Lamb; Taghi Manshouri; Rajyalakshmi Luthra; Zeev Estrov; Sherry Pierce; Mary Ann Richie; Gautam Borthakur; Marina Konopleva; Jorge Cortes; Srdan Verstovsek
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(32):5418-24.
2009: Arturo Vega-Ruiz; Jorge E Cortes; Matjaz Sever; Taghi Manshouri; Alfonso Quintás-Cardama; Rajyalakshmi Luthra; Hagop M Kantarjian; Srdan Verstovsek
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.
Leukemia research 2009;33(11):1481-4.
2009: Alfonso Quintás-Cardama; Hagop M Kantarjian; Taghi Manshouri; Deborah Thomas; Jorge Cortes; Farhad Ravandi; Guillermo Garcia-Manero; Alessandra Ferrajoli; Carlos E Bueso-Ramos; Srdan Verstovsek
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4760-6.
2009: Koyu Hoshino; Alfonso Quintás-Cardama; Jerald P Radich; Hongyui Dai; Hui Yang; Guillermo Garcia-Manero
Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia.
Leukemia research 2009;33(10):1361-6.
2009: Alfonso Quintás-Cardama; Jorge Cortes
Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?
Current oncology reports 2009;11(5):337-45.
2009: Alfonso Quintás-Cardama; Andrew Lamb; Jorge Cortes
Imatinib and beyond--exploring the full potential of targeted therapy for CML.
Nature reviews. Clinical oncology 2009;6(9):535-43.
2009: Alfonso Quintás-Cardama; Fabio Pires De Souza Santos; Andrew Lamb; Susan O'Brien; Stefan Faderl; Ahmed Awais; Gautam Borthakur; Jorge Cortes
Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure.
Cancer 2009;115(17):3935-43.
2009: Alfonso Quintás-Cardama; Xin Han; Andrew Lamb; Jorge Cortes
Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.
Blood 2009;114(2):261-3.
2009: Vince D Cataldo; Jorge Cortes; Alfonso Quintás-Cardama
Azacitidine for the treatment of myelodysplastic syndrome.
Expert review of anticancer therapy 2009;9(7):875-84.
2009: Roberto H Nussenzveig; Jorge Cortes; Matjaz Sever; Alfonso Quintás-Cardama; Patricia Ault; Taghi Manshouri; Carlos Bueso-Ramos; Josef T Prchal; Andrew Lamb; Srdan Verstovsek
Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001.
International journal of hematology 2009;90(1):58-63.
2009: Alfonso Quintás-Cardama; Jorge E Cortes; Susan O'Brien; Farhad Ravandi; Gautam Borthakur; David Liu; Eric Bleickardt; Tai-Tsang Chen; Hagop M Kantarjian
Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.
Cancer 2009;115(13):2912-21.
2009: Alfonso Quintás-Cardama; Andrew Lamb; Dan Jones; Jianqin Shan; Gautam Borthakur; Deborah Thomas; Steven Kornblau; Susan O'Brien; Jorge Cortes
Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy.
Blood 2009;113(25):6315-21.
2009: Alfonso Quintás-Cardama; Andrew Lamb; Farhad Ravandi; Susan O'Brien; Deborah Thomas; Gabriela Vidal-Senmache; William G Wierda; Steven M Kornblau; Jorge Cortes
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.
Cancer 2009;115(11):2482-90.
2009: Nitin Jain; Jorge Cortes; Alfonso Quintás-Cardama; Taghi Manshouri; Rajyalakshmi Luthra; Guillermo Garcia-Manero; Andrew Lamb; Srdan Verstovsek
Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.
Leukemia research 2009;33(6):837-9.
2009: Alfonso Quintás-Cardama; Hagop M Kantarjian; Jorge E Cortes
Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.
Cancer control : journal of the Moffitt Cancer Center 2009;16(2):122-31.
2009: Alfonso Quintás-Cardama; Jorge E Cortés
The next generation of therapies for chronic myeloid leukemia.
Clinical lymphoma & myeloma 2009;9 Suppl 4():S395-403.
2009: Alfonso Quintás-Cardama; Susan O'Brien
Targeted therapy for chronic lymphocytic leukemia.
Targeted oncology 2009;4(1):11-21.
2009: Srdan Verstovsek; Ayalew Tefferi; Andrew Lamb; Taghi Manshouri; Raja Luthra; Animesh Pardanani; Alfonso Quintás-Cardama; Farhad Ravandi; Patricia Ault; Carlos Bueso-Ramos; Jorge E Cortes
Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(1):368-73.
2008: Alfonso Quintás-Cardama; Alexander Lazar; Scott E Woodman; Kevin Kim; Merrick Ross; Patrick Hwu
Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib.
Nature clinical practice. Oncology 2008;5(12):737-40.
2008: Alfonso Quintás-Cardama; Jorge Cortes
Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases.
Future oncology (London, England) 2008;4(5):611-21.
2008: Alfonso Quintás-Cardama; Jorge Cortes
Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones.
Leukemia research 2008;32(8):1313-6.
2008: Alfonso Quintás-Cardama; Jorge Cortes
Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(14):4392-9.
2008: Alfonso Quintás-Cardama; Jorge Cortes
Therapeutic options for patients with clonal and idiopathic hypereosinophia.
Expert opinion on investigational drugs 2008;17(7):1039-50.
2008: Seth Politano; Diego Maselli; Maryam J Zenali; Andy Nguyen; Alfonso Quintás-Cardama
Bone marrow fibrosis and gelatinous atrophy associated with acute Epstein-Barr virus infection.
American journal of hematology 2008;83(7):606-7.
2008: Taghi Manshouri; Alfonso Quintás-Cardama; Roberto H Nussenzveig; Amos Gaikwad; Zeev Estrov; Josef T Prchal; Jorge E Cortes; Hagop M Kantarjian; Srdan Verstovsek
The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
Cancer science 2008;99(6):1265-73.
2008: Alfonso Quintás-Cardama; W Tong; Taghi Manshouri; Francisco Vega; P A Lennon; J Cools; D G Gilliland; F Lee; Jorge Cortes; Andrew Lamb; Guillermo Garcia-Manero
Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies.
Leukemia 2008;22(6):1117-24.
2008: Alfonso Quintás-Cardama; Jorge Cortes
Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies.
IDrugs : the investigational drugs journal 2008;11(5):356-72.
2008: Alfonso Quintás-Cardama
Experimental non-ATP-competitive therapies for chronic myelogenous leukemia.
Leukemia 2008;22(5):932-40.
2008: Alfonso Quintás-Cardama; Jorge Cortes
Management of patients with resistant or refractory chronic myelogenous leukemia.
Oncology (Williston Park, N.Y.) 2008;22(4):430-7; discussion 437, 442, 446 passim.
2008: Alfonso Quintás-Cardama; Jorge Cortes
Homoharringtonine for the treatment of chronic myelogenous leukemia.
Expert opinion on pharmacotherapy 2008;9(6):1029-37.
2008: Alfonso Quintás-Cardama; Antoine J Harb; Hesham M Amin; Srdan Verstovsek
Granulocytic sarcoma with massive scalp involvement.
American journal of hematology 2008;83(4):340-2.
2008: Alfonso Quintás-Cardama; Jorge E Cortés; Andrew Lamb
Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia.
Clinical lymphoma & myeloma 2008;8 Suppl 3():S82-8.
2008: Weiguo Zhang; Marina Konopleva; Yue-Xi Shi; Teresa McQueen; David Harris; Xiaoyang Ling; Zeev Estrov; Alfonso Quintás-Cardama; Donald Small; Jorge Cortes; Michael Andreeff
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Journal of the National Cancer Institute 2008;100(3):184-98.
2008: Srdan Verstovsek; Taghi Manshouri; Alfonso Quintás-Cardama; David Harris; Jorge Cortes; Francis Giles; Andrew Lamb; Waldemar Priebe; Zeev Estrov
WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(3):788-96.
2007: Alfonso Quintás-Cardama; Raymond K Yeh; Daniel Hollyman; Jolanta Stefanski; Clare Taylor; Yan Nikhamin; Gavin Imperato; Michel Sadelain; Isabelle Riviere; Renier J Brentjens
Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application.
Human gene therapy 2007;18(12):1253-60.
2007: Alfonso Quintás-Cardama; Andrew Lamb; Srdan Verstovsek
Treatment of systemic mastocytosis with denileukin diftitox.
American journal of hematology 2007;82(12):1124.
2007: Jorge Cortes; Alfonso Quintás-Cardama; Guillermo Garcia-Manero; Susan O'Brien; Dan Jones; Stefan Faderl; Theresa Ebarb; Francis Giles; Deborah Thomas; Andrew Lamb
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.
Cancer 2007;110(9):2000-6.
2007: Alfonso Quintás-Cardama; Andrew Lamb; Jorge Cortes
Tyrosine kinase inhibitors for chronic myelogenous leukemia.
The New England journal of medicine 2007;357(15):1557; author reply 1557-8.
2007: Alfonso Quintás-Cardama; Andrew Lamb; Jorge Cortes
Flying under the radar: the new wave of BCR-ABL inhibitors.
Nature reviews. Drug discovery 2007;6(10):834-48.
2007: Renier J Brentjens; Elmer B Santos; Yan Nikhamin; Raymond Yeh; Maiko Matsushita; Krista La Perle; Alfonso Quintás-Cardama; Steven M Larson; Michel Sadelain
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 1):5426-35.
2007: Alfonso Quintás-Cardama; Andrew Lamb; Susan O'Brien; Gautham Borthakur; John F Bruzzi; Reginald F Munden; Jorge Cortes
Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(25):3908-14.
2007: Matko Kalac; Alfonso Quintás-Cardama; Radovan Vrhovac; Andrew Lamb; Srdan Verstovsek
A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia.
Cancer 2007;110(5):955-64.
2007: Alfonso Quintás-Cardama; Srdan Verstovsek
Experience with oral interferon-alpha in patients with essential thrombocythemia and polycythemia vera.
American journal of hematology 2007;82(9):859.
2007: Jingxuan Pan; Alfonso Quintás-Cardama; Taghi Manshouri; Jorge Cortes; Andrew Lamb; Srdan Verstovsek
Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406.
Cancer science 2007;98(8):1223-5.
2007: J Pan; Alfonso Quintás-Cardama; Taghi Manshouri; Francis Giles; P Lamb; Ayalew Tefferi; Jorge Cortes; Andrew Lamb; Srdan Verstovsek
The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1.
Leukemia 2007;21(7):1395-404.
2007: Koyu Hoshino; Alfonso Quintás-Cardama; Huiling Yang; Blanca Sanchez-Gonzalez; Guillermo Garcia-Manero
Aberrant DNA methylation of the Src kinase Hck, but not of Lyn, in Philadelphia chromosome negative acute lymphocytic leukemia.
Leukemia 2007;21(5):906-11.
2007: Alfonso Quintás-Cardama; Don L Gibbons
Five-gene signature in non-small-cell lung cancer.
The New England journal of medicine 2007;356(15):1582-3; author reply 1583.
2007: Alfonso Quintás-Cardama; Andrew Lamb; Jorge Cortes
The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia.
Leukemia & lymphoma 2007;48(4):802-4.
2007: Alfonso Quintás-Cardama; Jorge Cortes
Evaluation of the L-stereoisomeric nucleoside analog troxacitabine for the treatment of acute myeloid leukemia.
Expert opinion on investigational drugs 2007;16(4):547-57.
2007: Alfonso Quintás-Cardama; Srdan Verstovsek
Is there still a role for interferon-alpha for newly diagnosed chronic myeloid leukemia in chronic phase?
Leukemia & lymphoma 2007;48(3):445-6.
2007: Hagop M Kantarjian; Francis Giles; Alfonso Quintás-Cardama; Jorge Cortes
Important therapeutic targets in chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(4):1089-97.
2007: Ruben A Mesa; Alfonso Quintás-Cardama; Srdan Verstovsek
Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia.
Current hematologic malignancy reports 2007;2(1):25-33.
2007: Alfonso Quintás-Cardama; Andrew Lamb; Guillermo Garcia-Manero; Susan O'Brien; Stefan Faderl; Farhad Ravandi; Francis Giles; Deborah Thomas; William G Wierda; Jorge Cortes
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
Leukemia & lymphoma 2007;48(2):283-9.
2007: Alfonso Quintás-Cardama; Andrew Lamb; Guillermo Garcia-Manero; Susan O'Brien; Stefan Faderl; Zeev Estrov; Francis Giles; Anthony J Murgo; Nakia Ladie; Srdan Verstovsek; Jorge Cortes
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
Cancer 2007;109(2):248-55.
2007: Jingxuan Pan; Alfonso Quintás-Cardama; Hagop M Kantarjian; Cem Akin; Taghi Manshouri; Peter Lamb; Jorge E Cortes; Ayalew Tefferi; Francis Giles; Srdan Verstovsek
EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
Blood 2007;109(1):315-22.
2006: Alfonso Quintás-Cardama; Andrew Lamb; Jorge Cortes
Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.
Future oncology (London, England) 2006;2(6):655-65.
2006: Srdan Verstovsek; Alfonso Quintás-Cardama; Andrew Lamb; Ayalew Tefferi
Experimental therapy in myelofibrosis with myeloid metaplasia.
Expert opinion on investigational drugs 2006;15(12):1555-63.
2006: Srdan Verstovsek; Francis Giles; Alfonso Quintás-Cardama; Nichole Perez; Farhad Ravandi-Kashani; Miloslav Beran; Emil J Freireich; Andrew Lamb
Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
Hematological oncology 2006;24(4):181-8.
2006: Srdan Verstovsek; Francis Giles; Alfonso Quintás-Cardama; Taghi Manshouri; Ly Huynh; Paul Manley; Jorge Cortes; Ayalew Tefferi; Andrew Lamb
Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells.
Leukemia research 2006;30(12):1499-505.
2006: Srdan Verstovsek; Cem Akin; Taghi Manshouri; Alfonso Quintás-Cardama; Ly Huynh; Paul Manley; Ayalew Tefferi; Jorge Cortes; Francis Giles; Andrew Lamb
Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.
Leukemia research 2006;30(11):1365-70.
2006: Cecilia Arana-Yi; Alfonso Quintás-Cardama; Francis Giles; Deborah Thomas; Antonio Carrasco-Yalan; Jorge Cortes; Andrew Lamb; Srdan Verstovsek
Advances in the therapy of chronic idiopathic myelofibrosis.
The oncologist 2006;11(8):929-43.
2006: Nada Orsolic; Mirna Golemovic; Alfonso Quintás-Cardama; Barbara Scappini; Taghi Manshouri; Joya Chandra; Ivan Basic; Francis Giles; Andrew Lamb; Srdan Verstovsek
Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells.
Cancer science 2006;97(9):952-60.
2006: Alfonso Quintás-Cardama; Jorge E Cortes
Chronic myeloid leukemia: diagnosis and treatment.
Mayo Clinic proceedings. Mayo Clinic 2006;81(7):973-88.
2006: Alfonso Quintás-Cardama; Hagop M Kantarjian; Francis Giles; Srdan Verstovsek
Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders.
Seminars in thrombosis and hemostasis 2006;32(4 Pt 2):409-16.
2006: Alfonso Quintás-Cardama; Jorge Cortes
Kinase inhibitors in chronic myelogenous leukemia.
Clinical advances in hematology & oncology : H&O 2006;4(5):365-74.
2002: Alfonso Quintás-Cardama
Acquired amegakaryocytic thrombocytopenic purpura successfully treated with limited cyclosporin A therapy.
European journal of haematology 2002;69(3):185-6.